Literature DB >> 2669966

Expression of a human liver cytochrome P-450 protein with tolbutamide hydroxylase activity in Saccharomyces cerevisiae.

W R Brian1, P K Srivastava, D R Umbenhauer, R S Lloyd, F P Guengerich.   

Abstract

The human liver cytochrome P-450 (P-450) proteins responsible for catalyzing the oxidation of mephenytoin, tolbutamide, and hexobarbital are encoded by a multigene family (CYP2C). Although several cDNA clones and proteins related to this "P-450MP" family have been isolated, assignment of specific catalytic activities remains uncertain. Sulfaphenazole was found to inhibit tolbutamide hydroxylation to a greater extent than mephenytoin or hexobarbital hydroxylation. The inhibition by sulfaphenazole was competitive for tolbutamide and hexobarbital hydroxylation but with much different Ki values (5 vs 480 microM, respectively). Inhibition of mephenytoin hydroxylase was not competitive. The results suggest that different P-450 proteins in the P450MP family may be involved in the metabolism of these compounds. A cDNA clone (MP-8) related to the P-450MP family, isolated from a bacteriophage lambda gt11 human liver library, was expressed in Saccharomyces cerevisiae by using the pAAH5 expression vector. Yeast transformed with pAAH5 containing the MP-8 sequence (pAAH5/MP-8) showed a ferrous-CO spectrum typical of the P-450 proteins. Immunoblotting with anti-P450MP revealed that pAAH5/MP-8 microsomes contained a protein with an Mr similar to that of P-450MP-1 (approximately 48,000) that was not present in microsomes from yeast transformed with pAAH5 alone (1.7 X 10(4) molecules of the expressed P-450 per cell). Microsomes from pAAH5/MP-8 contained no detectable mephenytoin 4'-hydroxylase activity but were more active in tolbutamide hydroxylation, on a nanomoles of P-450 basis, than human liver microsomes. The pAAH5/MP-8 microsomes also contained hexobarbital 3'-hydroxylase activity, although the enrichment compared to liver microsomes was not great with respect to the tolbutamide hydroxylase activity.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2669966     DOI: 10.1021/bi00438a014

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  14 in total

1.  A screening test for slow metabolisers of tolbutamide.

Authors:  M A Page; J S Boutagy; G M Shenfield
Journal:  Br J Clin Pharmacol       Date:  1991-06       Impact factor: 4.335

2.  Genetic polymorphism of enzymes involved in xenobiotic metabolism and the risk of lung cancer.

Authors:  Chikako Kiyohara; Taro Shirakawa; Julian M Hopkin
Journal:  Environ Health Prev Med       Date:  2002-05       Impact factor: 3.674

Review 3.  Molecular basis of polymorphic drug metabolism.

Authors:  A K Daly
Journal:  J Mol Med (Berl)       Date:  1995-11       Impact factor: 4.599

Review 4.  Differential kinetics of phenytoin in elderly patients.

Authors:  K A Bachmann; R J Belloto
Journal:  Drugs Aging       Date:  1999-09       Impact factor: 3.923

5.  Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes.

Authors:  C J Doecke; M E Veronese; S M Pond; J O Miners; D J Birkett; L N Sansom; M E McManus
Journal:  Br J Clin Pharmacol       Date:  1991-02       Impact factor: 4.335

6.  Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans.

Authors:  D Busse; J Cosme; P Beaune; H K Kroemer; M Eichelbaum
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-12       Impact factor: 3.000

Review 7.  Development and Uses of Offline and Web-Searchable Metabolism Databases - The Case of Benzo[a]pyrene.

Authors:  Slobodan P Rendic; Frederick P Guengerich
Journal:  Curr Drug Metab       Date:  2018       Impact factor: 3.731

8.  In vitro forecasting of drugs that may interfere with codeine bioactivation.

Authors:  P Dayer; J Desmeules; R Striberni
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1992 Apr-Jun       Impact factor: 2.441

9.  Endotoxin administration to humans inhibits hepatic cytochrome P450-mediated drug metabolism.

Authors:  S I Shedlofsky; B C Israel; C J McClain; D B Hill; R A Blouin
Journal:  J Clin Invest       Date:  1994-12       Impact factor: 14.808

10.  Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily.

Authors:  M E Veronese; C J Doecke; P I Mackenzie; M E McManus; J O Miners; D L Rees; R Gasser; U A Meyer; D J Birkett
Journal:  Biochem J       Date:  1993-01-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.